Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionFDLS - Inspire Fidelis Multi Factor ETF
Latest Disclosed Ownership64,467 shares
Latest Disclosed Value $ 1,487,898
FDLS - Inspire Fidelis Multi Factor ETF reports 61.71% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On April 28, 2026 - FDLS - Inspire Fidelis Multi Factor ETF filed a NPORT-P form disclosing ownership of 64,467 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $1,487,898 USD as of February 28, 2026. The entity filed a previous NPORT-P on October 29, 2025 disclosing 39,865 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 61.71% during the quarter. The current value of the position is $2,030,066 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-28 2026-02-28 NP CATALYST PHARMAC EC US14888U1016 64,467 24,602 61.71 1,488 81.34 0.8877
2025-10-29 2025-08-31 NP CATALYST PHARMAC EC US14888U1016 39,865 6,802 20.57 821 -0.61 0.8115
2025-07-29 2025-05-31 NP CATALYST PHARMAC EC US14888U1016 33,063 -3,987 -10.76 825 -2.71 1.0229
2025-04-28 2025-02-28 NP CATALYST PHARMAC EC US14888U1016 37,050 -3,710 -9.10 848 -5.67 1.0478
2025-01-28 2024-11-30 NP CATALYST PHARMAC EC US14888U1016 40,760 40,760 900 0.9505
2023-07-27 2023-05-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 0 -29,065 -100.00 0 -100.00
2023-04-28 2023-02-28 NP CATALYST PHARMACEUTICALS EC US14888U1016 29,065 -2,066 -6.64 444 -15.13 0.8361
2023-01-26 2022-11-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 31,131 -3,751 -10.75 522 10.59 1.1128
2022-10-28 2022-08-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 34,882 34,882 472 1.1420
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.